Nov 6, 2025 04:22AM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners

Nov 5, 2025 03:59PM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $44 at RBC Capital

Oct 20, 2025 07:08AM H.C. Wainwright Assumes NewAmsterdam Pharma Co NV (NAMS) at Buy

Oct 6, 2025 04:32AM NewAmsterdam Pharma (NAMS) spreader of November 22.50 and 30 puts

Aug 25, 2025 05:13AM Wells Fargo Starts NewAmsterdam Pharma Co NV (NAMS) at Overweight

Aug 18, 2025 08:02AM EMA accepts NewAmsterdam obicetrapib applications for review

Aug 11, 2025 08:23AM Piper Sandler Sees Strong Momentum Ahead for NewAmsterdam Pharma Co NV (NAMS)

Aug 6, 2025 10:18AM TD Cowen Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)

Jul 30, 2025 08:26AM NewAmsterdam Pharma reports reduction in Alzheimer's biomarkers in trial

Jul 17, 2025 06:30AM Goldman Sachs Starts NewAmsterdam Pharma Co NV (NAMS) at Neutral

Jun 17, 2025 05:18AM Citi Starts NewAmsterdam Pharma Co NV (NAMS) at Buy

Jun 12, 2025 07:22AM Cantor Fitzgerald Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)

Jun 12, 2025 07:15AM Stifel Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)

Jun 9, 2025 04:06PM Stifel Starts NewAmsterdam Pharma Co NV (NAMS) at Buy

Jun 9, 2025 07:05AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Trial

Jun 4, 2025 06:53AM Cantor Fitzgerald Starts NewAmsterdam Pharma Co NV (NAMS) at Overweight

Jun 3, 2025 05:52AM RBC Capital Reiterates Outperform Rating on NewAmsterdam Pharma Co NV (NAMS)

May 7, 2025 07:15AM NewAmsterdam Pharma (NAMS) Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals, Presented

Apr 17, 2025 04:02PM NewAmsterdam Pharma (NAMS) appoints Adele Gulfo to Board

Feb 27, 2025 07:18AM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $52 at Scotiabank

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA

Jan 10, 2025 08:03AM NewAmsterdam Pharma (NAMS) Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

Jan 3, 2025 08:23AM Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies

Dec 30, 2024 06:06AM H.C. Wainwright Starts NewAmsterdam Pharma Co NV (NAMS) at Buy

Dec 11, 2024 07:15AM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $47 at Scotiabank

Dec 10, 2024 04:36PM NewAmsterdam Pharma (NAMS) Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024 07:00AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib

Nov 20, 2024 04:10PM NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners

Nov 20, 2024 07:01AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with AS

Nov 19, 2024 07:57AM Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)

Oct 21, 2024 07:14AM Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)

Sep 23, 2024 07:20AM Piper Sandler Reiterates Overweight Rating on NewAmsterdam Pharma Co NV (NAMS)

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Aug 27, 2024 08:18AM TD Cowen Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)

Jul 29, 2024 08:06AM NewAmsterdam Pharma (NAMS) Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Jul 26, 2024 04:01PM NewAmsterdam Pharma (NAMS) to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday

Jul 18, 2024 08:06AM NewAmsterdam Pharma (NAMS) Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors